Hims Hers Health Inc (HIMS)vsMerck & Company Inc (MRK)
HIMS
Hims Hers Health Inc
$26.33
-5.66%
HEALTHCARE · Cap: $6.97B
MRK
Merck & Company Inc
$110.95
+0.84%
HEALTHCARE · Cap: $276.38B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2669% more annual revenue ($65.01B vs $2.35B). MRK leads profitability with a 28.1% profit margin vs 5.5%. HIMS appears more attractively valued with a PEG of 2.63. MRK earns a higher WallStSmart Score of 59/100 (C).
HIMS
Hold50
out of 100
Grade: D+
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+24.9%
Fair Value
$39.60
Current Price
$26.33
$13.27 discount
Margin of Safety
-15.1%
Fair Value
$96.48
Current Price
$110.95
$14.47 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 25 in profit
Revenue surging 28.4% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Trading at 11.1x book value
Distress zone — elevated risk
5.5% margin — thin
Operating margin of 2.7%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Return on Equity, Revenue Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Profit Margin. A P/E of 59.9x leaves little room for execution misses. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
HIMS profiles as a growth stock while MRK is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.31 — expect wider price swings.
HIMS is growing revenue faster at 28.4% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 50/100), backed by strong 28.1% margins. HIMS offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?